AGP Picks
View all

Wyoming Tech Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wyoming Tech Reporter.

Press releases published on May 6, 2026

Ground Zero Intelligence Launches $GZI Utility Token to Power High-Growth AI Ecosystem Anchored by ProWebChat
Crypto News Today: AlphaPepe Presale Crosses $1.1M Whilst Bitcoin Price Prediction Points To $250,000
GoEnhance AI Publishes Tutorial-Style Workflow for Testing Seedance 2.0 and AI Dance Video Outputs
Axavive Skin Exploding in 2026: Can This “Golden Seed Switch” Really Transform Your Skin?
GPT Image 2 Vs Nano Banana 2: A Practical Guide for Choosing the Right AI Image Model
Orezone Provides Notice of First Quarter 2026 Results
Inspired Entertainment Extends Long-Term Agreement with Paddy Power for Gaming Terminals and Content
Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
reAlpha Reduces Workforce by Approximately 25% and Consolidates Vendor Spend, Targeting $2 Million in Annualized Savings as AI Advancements Drive Organizational Efficiency
MemoPryl Investigated: Full MemoPryl Consumer Report Reviewed Shocking Hidden Risks & Fake Nootropic Claims
GlucoTru Pro 2026: Claims Examined, Pricing Verified & What Consumers Should Confirm Before Buying
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Seegnal Inc. Announces Update to Delay in Filing 2025 Annual Financial Statements and Related Management Discussion and Analysis
CEA Industries Announces Board Composition Change
argenx to Present at BofA Securities 2026 Health Care Conference
Alvotech Q1 2026 Financial Results
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
MKS Inc. Reports First Quarter 2026 Financial Results
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Share this page:

Sign up for:

Wyoming Tech Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.